Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials
Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials
复制标题
DOI：
10.1093/annonc/mdh476
复制
发表时间：
2004-12-01
影响因子：
50.5
通讯作者：
Tanimoto, M
中科院分区：
文献类型：
--
作者：
Hotta, K;Matsuo, K;Tanimoto, M
背景：据报道，单药新药物具有良好的疗效和生存效果，但铂基双药仍是晚期非小细胞肺癌（NSCLC）的标准化疗方案。本研究的目的是通过对以铂为基础的双重药物治疗与单一新药治疗进行meta分析，评估铂治疗晚期NSCLC的有效性。方法：我们进行了文献检索，以确定在1994年至2003年间进行的试验，比较铂双药加一种新药与单独一种新药在先前未经治疗的晚期NSCLC患者中的应用。结果分析为反应、生存和毒性。结果：8项试验纳入了2374例患者。以铂为基础的双重药物产生的总体（完全和部分）缓解率比单独使用新药物高出约两倍[优势比= 2.32；95%置信区间(Cl) = 1.68-3.20]。以铂为基础的双重治疗也与13%的生存延长相关(风险比= 0.87;95% CI = 0.80-0.94， P
Background: Single new agents reportedly produce promising response and survival effects, but platinum-based doublets remain the standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). The aim of this study was to evaluate the effectiveness of platinum for advanced NSCLC by carrying out a meta-analysis of trials that compared platinum-based doublets with single new agent therapy alone.Methods: We carried out a literature search to identify trials, conducted between 1994 and 2003, comparing a doublet of platinum plus a new agent with a new agent alone in previously untreated patients with advanced NSCLC. Outcomes analysed were response, survival and toxicity.Results: Eight trials encompassing 2374 patients were identified. Platinum-based doublets produced an approximately two-fold higher overall (complete and partial) response rate than the new agent alone [odds ratio = 2.32; 95% confidence interval (Cl) = 1.68-3.20]. Platinum-based doublet therapy was also associated with a 13% prolongation of survival (hazard ratio = 0.87; 95% CI = 0.80-0.94, P